Novel
chimeric peptides (GEP44 and EP series)
were produced by Genscript (Piscataway, NJ) or in-house using a microwave
assisted CEM liberty Blue peptide synthesizer. Peptides were synthesized
with C-terminal amidation and K12-azido modification (in place for
future bioconjugations) and confirmed for sequence via MS/MS and purity
by RP-HPLC (all at least >95%) (
Figure S4–S9).
GLP-1,
glucagon, Ex-4, Ex(9–39), PYY
3–36, and
adenosine were obtained from Sigma-Aldrich.
BIIE024643 was
obtained from Tocris Biosciences (Minneapolis, MN).
Milliken B.T., Elfers C., Chepurny O.G., Chichura K.S., Sweet I.R., Borner T., Hayes M.R., De Jonghe B.C., Holz G.G., Roth C.L, & Doyle R.P. (2021). Design and Evaluation of Peptide Dual-Agonists of GLP-1 and NPY2 Receptors for Glucoregulation and Weight Loss with Mitigated Nausea and Emesis. Journal of Medicinal Chemistry, 64(2), 1127-1138.